Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 20 and 75 years old.
- People whose blood test results show healthy enough levels of white blood cells, infection-fighting cells (neutrophils), and platelets (cells that help blood clot).
- People whose blood test results show that their kidneys are working well enough (confirm with trial site for exact values).
- People whose blood test results show that their liver's bilirubin level is low enough (confirm with trial site for exact value).
- People who are fully active or have only minor restrictions in physical activity, as measured by a standard oncology scoring system called ECOG Performance Status 0 or 1.
- People who have full legal capacity to make their own decisions.
- People who have been newly diagnosed with a specific type of stomach cancer (gastric adenocarcinoma, including a type affecting the junction between the oesophagus and stomach called Siewert III), where the cancer has spread to the lining of the abdomen only to a limited degree, or where cancer cells have been found in fluid washed from the abdomen but no visible spread is present.
Who may not be able to join:
- People who have had another cancer diagnosed within the last 3 years, or any cancer that shows signs of coming back.
- People whose newly diagnosed stomach cancer has already been treated with chemotherapy before the trial (either by injection into the bloodstream or directly into the abdomen).
- People with certain serious ongoing health conditions, including significant liver scarring (cirrhosis rated Child B or worse), severe heart failure, or poorly controlled chronic lung disease.
- People whose overall health and surgical risk is rated at a certain level or higher under a standard anaesthesia risk classification system (ASA Class 3 or above).
- People who are pregnant or breastfeeding.
- People who are known to be unable to tolerate the specific chemotherapy medicines used in this trial, which include paclitaxel (for all participants), and either capecitabine and oxaliplatin, or cisplatin and 5-fluorouracil, depending on which treatment group a person would be in.
- People whose cancer has spread to distant parts of the body such as the liver, lungs, or bones (spread to the abdominal lining, certain abdominal lymph nodes, or ovaries does not apply here).
- People whose cancer has spread extensively across the abdominal lining, beyond the limited level required for this trial.
- People diagnosed with Siewert Type I or Type II adenocarcinoma of the junction between the oesophagus and stomach.
- People whom the trial investigators consider unsuitable for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: I-Rue Lai, MDPHD, National Taiwan University Hospital
Phone: 0910012718
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
6-month disease control rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.